Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING NA

RelayPro Thoracic Stent-Graft in Subjects With Thoracic Aortic Aneurysms and Penetrating Atherosclerotic Ulcers

NCT02818972 · View on ClinicalTrials.gov ↗

Study Summary

Investigate the safety and effectiveness of the RelayPro Thoracic Stent-Grafts in subjects with thoracic aortic aneurysms (TAA) and penetrating atherosclerotic ulcers (PAU) of the descending thoracic aorta.

Interventions

  • DEVICE RelayPro

Study Locations (20)

Massachusetts

  • Tufts Medical Center — Boston
  • Beth Israel Deaconess Medical Center / Harvard Medical School — Boston
  • Baystate Medical Center — Springfield

California

  • University of California, Irvine — Irvine
  • Long Beach Memorial Hospital — Long Beach

Indiana

  • Indiana University Health — Indianapolis
  • St. Vincent Heart Center — Indianapolis

Ohio

  • University Hospitals — Cleveland
  • Cleveland Clinic Foundation — Cleveland

Pennsylvania

  • University of Pennsylvania Medical Center / Penn Presbyterian — Philadelphia
  • Lankenau Medical Center — Wynnewood

Alabama

  • University of Alabama-Birmingham — Birmingham

Arizona

  • Arizona Heart Institute — Phoenix

Connecticut

  • Hartford Hospital — Hartford

Trial Details

FieldValue
Enrollment Target 110 participants
Start Date 2017-05-10
Est. Completion 2025-12
Phase NA

Sponsor

Bolton Medical

36 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02818972

The ClinicalTrials.gov registry entry for NCT02818972 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bolton Medical, which has 36 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Aortic Aneurysm, Thoracic appearing as the primary indexed condition, and to 1 intervention — of which RelayPro is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT02818972 reports 20 study locations spanning 14 distinct geographic areas — top geographies include Massachusetts, California, Indiana. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT02818972 about?

NCT02818972 is a clinical study titled "RelayPro Thoracic Stent-Graft in Subjects With Thoracic Aortic Aneurysms and Penetrating Atherosclerotic Ulcers". Investigate the safety and effectiveness of the RelayPro Thoracic Stent-Grafts in subjects with thoracic aortic aneurysms (TAA) and penetrating atherosclerotic ulcers (PAU) of the descending thoracic aorta.

What is the current status of trial NCT02818972?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 110 participants. The study started on 2017-05-10. Estimated completion is 2025-12.

What conditions does trial NCT02818972 study?

This clinical trial studies the following conditions: Aortic Aneurysm, Thoracic, Penetrating Ulcer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT02818972?

The interventions under investigation include: RelayPro (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT02818972?

This trial is sponsored by Bolton Medical, which has 36 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT02818972 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial